EA200700500A1 - Совокупность лекарственных форм и способ её введения - Google Patents

Совокупность лекарственных форм и способ её введения

Info

Publication number
EA200700500A1
EA200700500A1 EA200700500A EA200700500A EA200700500A1 EA 200700500 A1 EA200700500 A1 EA 200700500A1 EA 200700500 A EA200700500 A EA 200700500A EA 200700500 A EA200700500 A EA 200700500A EA 200700500 A1 EA200700500 A1 EA 200700500A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dosage form
dosage forms
dosage
dose
introduction
Prior art date
Application number
EA200700500A
Other languages
English (en)
Other versions
EA010627B1 (ru
Inventor
Куртис Райт
Роберт Колуччи
Ахмед Эль - Тахтави
Original Assignee
Еуро-Селтик С. А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еуро-Селтик С. А. filed Critical Еуро-Селтик С. А.
Publication of EA200700500A1 publication Critical patent/EA200700500A1/ru
Publication of EA010627B1 publication Critical patent/EA010627B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к совокупности лекарственных форм, включающей первую лекарственную форму и вторую лекарственную форму, каждая из которых содержит терапевтический агент, такой как опиоид; при этом величина дозы второй лекарственной формы больше, чем величина дозы первой лекарственной формы, и Cустойчивого состояния и параметры AUC в устойчивом состоянии у первой лекарственной формы и второй лекарственной формы пропорциональны величинам доз и Cединичной дозы второй лекарственной формы меньше, чем минимальный уровень пропорциональности доз по отношению к первой лекарственной форме. Данное изобретение относится также к способам введения таких лекарственных форм пациенту, а также к наборам, включающим такие лекарственные формы и инструкции по введению лекарственных форм пациенту. Изобретатели полагают, что лекарственные формы и способы согласно данному изобретению обеспечивают большую безопасность и приемлемость для пациентов.
EA200700500A 2004-09-01 2005-08-30 Совокупность дозированных лекарственных форм, содержащих опиоид EA010627B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60635404P 2004-09-01 2004-09-01
PCT/US2005/030892 WO2006028830A2 (en) 2004-09-01 2005-08-30 Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax

Publications (2)

Publication Number Publication Date
EA200700500A1 true EA200700500A1 (ru) 2007-08-31
EA010627B1 EA010627B1 (ru) 2008-10-30

Family

ID=35759199

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700500A EA010627B1 (ru) 2004-09-01 2005-08-30 Совокупность дозированных лекарственных форм, содержащих опиоид

Country Status (15)

Country Link
US (2) US9326959B2 (ru)
EP (1) EP1786404A2 (ru)
JP (1) JP4997109B2 (ru)
KR (2) KR20070048272A (ru)
CN (1) CN101010072A (ru)
AU (1) AU2005282784B2 (ru)
BR (1) BRPI0515600A (ru)
CA (1) CA2578540A1 (ru)
EA (1) EA010627B1 (ru)
IL (1) IL181600A0 (ru)
MX (1) MX2007002135A (ru)
NO (1) NO20071352L (ru)
UA (1) UA85750C2 (ru)
WO (1) WO2006028830A2 (ru)
ZA (1) ZA200700620B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en) * 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068256A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-substance
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
PL399450A1 (pl) * 2009-08-31 2013-01-21 Depomed, Inc Utrzymujace sie w zoladku kompozycje farmaceutyczne do natychmiastowego i przedluzonego uwalniania acetaminofenu
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US10322120B2 (en) 2012-07-31 2019-06-18 Persion Pharmaceuticals Llc Treating pain in patients with hepatic impairment
US20140161879A1 (en) * 2012-07-31 2014-06-12 Zogenix, Inc. Treating pain in patients with hepatic impairment
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004922A1 (en) 1986-12-25 1988-07-14 Teysan Pharmaceuticals Co., Ltd. Slowly soluble granule and persistently effective composite granule prepared therefrom
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ES2200158T3 (es) * 1996-03-08 2004-03-01 Nycomed Danmark Aps Cmpuesto de dosificacion de unidades multiples, de liberacion modificada.
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6806294B2 (en) * 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
RU2230556C2 (ru) * 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
BR0008059A (pt) 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
UA81224C2 (ru) * 2001-05-02 2007-12-25 Euro Celtic S A Дозированная форма оксикодона и ее применение
US6874926B2 (en) * 2001-11-26 2005-04-05 Nokia Corporation Illumination system for an electronic device
DK200200669A (da) * 2002-05-02 2003-11-03 Schur Packaging Systems As Fremgangsmåde og apparat til fyldning af indhold i folieposer samt emballageemne til anvendelse ved fremgangsmåden og i apparatet

Also Published As

Publication number Publication date
WO2006028830A2 (en) 2006-03-16
US9034377B2 (en) 2015-05-19
CN101010072A (zh) 2007-08-01
IL181600A0 (en) 2007-07-04
CA2578540A1 (en) 2006-03-16
US20080132532A1 (en) 2008-06-05
UA85750C2 (ru) 2009-02-25
US9326959B2 (en) 2016-05-03
MX2007002135A (es) 2007-04-02
AU2005282784A1 (en) 2006-03-16
NO20071352L (no) 2007-05-30
ZA200700620B (en) 2008-04-30
WO2006028830A3 (en) 2006-05-26
US20140187572A1 (en) 2014-07-03
KR20080046751A (ko) 2008-05-27
AU2005282784B2 (en) 2008-06-19
EP1786404A2 (en) 2007-05-23
BRPI0515600A (pt) 2008-07-29
EA010627B1 (ru) 2008-10-30
JP4997109B2 (ja) 2012-08-08
JP2008511657A (ja) 2008-04-17
KR20070048272A (ko) 2007-05-08

Similar Documents

Publication Publication Date Title
EA200700500A1 (ru) Совокупность лекарственных форм и способ её введения
CY1120445T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
RU2017134443A (ru) Способ лечения с применением традипитанта
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
ATE367816T1 (de) Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
ECSP045140A (es) Formulaciones farmacéuticas derivadas del platino
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
EA201500293A1 (ru) Антихолинэргическая нейропротективная композиция и способы
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
ATE405272T1 (de) Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
EA201891575A1 (ru) Составы для лечения рака мочевого пузыря
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
Murakami et al. Humanin ameliorates diazepam-induced memory deficit in mice
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
Jhun et al. Vitamin D attenuates pain and cartilage destruction in OA animals via enhancing autophagic flux and attenuating inflammatory cell death
DK1656131T3 (da) Anvendelse af betain til behandling claudicatio intermittens
EA201590847A1 (ru) Новые ингибиторы rock
RU2013120345A (ru) Новые способы лечения инфекции, вызванной вирусом гепатита с
EA201301024A1 (ru) Способ уменьшения подобных гриппу симптомов, ассоциированных с внутримышечным введением интерферона, при использовании режима быстрого титрования повышающейся дозой
NO20024683L (no) Terapier med oppdelte doser som har vaskulirt skadende aktivitet
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ KG MD TJ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM RU